AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02663726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written advice
Description: Written advice about physical activity
Study NCT02913313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986207
Description: Specified dose on specified days
Study NCT02257762 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LNS
Description: Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients
Study NCT02257762 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Corn-soy blend ++ (CSB++)
Description: Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.
Study NCT02913313 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT02913313 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT04080206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 188-0551 Spray
Description: Applied topically twice daily for two weeks
Study NCT04080206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD
Description: Applied topically twice daily for two weeks
Study NCT03742427 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasonography
Description: optic nerve sheath diameter measurement will be done by ultrasonography on both eyes
Study NCT04119570 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CKD Report Card
Description: The CKD Report Card is a handout based on a NKDEP Educational Sheet that includes basic information about kidney disease and spaces where patient can record information about their own kidney disease
Study NCT04298762 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No peer comparison email
Description: The comparison group received no email communication on their cancer stage documentation activity.
Study NCT04298762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer comparison email
Description: The intervention group received three separate emails with individualized data on their cancer stage documentation activity in the previous 1-3 months. The email described the number and percent of attributed patients for whom cancer stage was documented, and included a figure showing their staging documentation rate compared to their peers.
Study NCT01555229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent subglottic secretion drainage
Description: Subglottic secretion drainage is performed using a specially designed endotracheal tube with a separate dorsal lumen that opens immediately above the endotracheal cuff.
Study NCT02257762 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sprinkles
Description: Multiple micronutrient powder packaged in sachet.
Study NCT01555229 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous subglottic secretion drainage
Description: Subglottic secretion drainage is performed using a specially designed endotracheal tube with a separate dorsal lumen that opens immediately above the endotracheal cuff.
Study NCT01765894 — intervention group
Intervention type: OTHER
Intervention: 45 minutes of moderate exercise at the fasted state. Before test day 2: 3 days of carbohydrate loading.
Study NCT00995254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHI counseling
Description: The SHI will be delivered in three different individualized counseling sessions: the initial in person counseling (30-45 minutes), at 1 week in person or telephone counseling (15-30 minutes) and at 1 month in person counseling (15-30 minutes). During the initial counseling, CHWs will emphasize the health hazards of SHS exposure towards young children and its possible illness outcomes. Then subjects will be asked to assess the SHS exposure of children in the household (e.g., estimating the number of hours for SHS exposure on the child per week or day) and the source of SHS. The concept of smoking hygiene and non-smoking household policy will be discussed and any potential barriers ascertained. Furthermore, the CHWs will use the transtheoretical model of Prochaska to assess the stage of readiness of the household member to change smoking behavior existing in the household. Individuals who wish to quit smoking will receive a brief advice on quitting smoking.
Study NCT02798926 — intervention group
Intervention type: DEVICE
Intervention: polyethylene bag
Description: The infant will be wrapped in a polyethylene bag 15 min before starting central venous catheter placement
Study NCT01091636 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Chemotherapy
Description: 41.5 oC injected into the perfusion cisplatin (75 mg/m2)during 90min
Study NCT04765605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WeFlow-Tbranch Stent Graft System
Description: The single-embedded branch thoracic aorta stent graft system consists of the thoracic aorta stent graft system and the branch stent system. The main chest embedded stent graft system consists of the main chest embedded stent graft and its system conveyor, and the branch stent system consists of branch stents and its conveyor. The main chest embedded stent graft and the branch stent are pre-installed in the conveyor
Study NCT02296060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 6 minutes walking test
Study NCT03227367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: other : PRF
Description: mononuclear cells from the peripheral blood of chronic periodontitis patients were intervened with PRF, BCP and PRF/BCP combination
Study NCT03227367 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: other : PRF
Description: mononuclear cells from the peripheral blood of chronic periodontitis patients were intervened with PRF, BCP and PRF/BCP combination
Study NCT00940004 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cell vaccination
Description: Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
Study NCT00940004 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous dendritic cell vaccination
Description: Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
Study NCT02024984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate
Description: Group A (study group) 'Luteal Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting on day 2 of the cycle induced by MPA for another menstrual cycle.~Group B (control group)'Follicular Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting on day 2 of the cycle induced by MPA, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days for another menstrual cycle.
Study NCT02024984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate
Description: Group A (study group) 'Luteal Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting on day 2 of the cycle induced by MPA for another menstrual cycle.~Group B (control group)'Follicular Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting on day 2 of the cycle induced by MPA, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days for another menstrual cycle.
Study NCT04106154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kinesiology Support
Description: 12 week physical activity group led by Kinesiologist. The intervention will be used to increase confidence in the participants by providing physical activity education and a variety of activities.
Study NCT03973476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone care support by midwife
Description: Mothers can call the midwife's telephone every working day from 8 a.m. to 8 p.m.
Study NCT01953952 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo transoral eHNS
Study NCT01953952 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT
Study NCT01953952 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT
Study NCT01953952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT01953952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Given IV
Study NCT01953952 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01953952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01953952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01953952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01545960 — intervention group
Intervention type: OTHER
Intervention: not applicable in this study
Description: No actual interventions will be administered for this study.
Study NCT02073487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: antibody-drug conjugate of trastuzumab and emtansine
Study NCT02073487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: anti-Her2 monoclonal antibody
Study NCT02073487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Dual tyrosine kinase inhibitor (HER2 and EGFR)
Study NCT00680719 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IBFT /HIV prevention
Description: Integrated Behavioral and Family Therapy (IBGT) with HIV prevention.
Study NCT02073487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: albumin-bound paclitaxel. chemotherapy - microtubule inhibitor.
Study NCT02073487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: chemotherapy - microtubule inhibitor
Study NCT02073487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: anti-HER2 monoclonal antibody
Study NCT04244344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fall prevention measures
Description: High fall risk signage, information sheet, High fall risk bracelet, verbal instructions
Study NCT02660125 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial scratch injury
Description: midluteal single endometrial strip will be taken using a Novak curett under general anasthesia to avoid discomfort and cramping and to proceed to cervical dilatation in case of forbidden cervix
Study NCT00537433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pictogram
Description: The plain language, pictogram-based medication instruction sheets (available in English and Spanish) utilize pictograms to convey information about the medication name, indication, dose, dose frequency, and length of treatment, along with information about preparation and storage. The sheets also include a medication log for parents to keep track of when they administer the medication.~Research staff reference the sheets as they demonstrate dosing with a standardized dosing instrument; teachback is performed to reinforce concepts. For medications in which a standardized dosing instrument was not included at dispensing, a standardized oral dosing syringe is provided for the caregiver to use at home. After counseling, the caregiver is given the instruction sheet to take home.
Study NCT00680719 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IBFT
Description: Integrated Behavioral and Family Therapy (IBFT).
Study NCT03593473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Description: Six intranasal sprays of oxytocin. Each insufflation delivers 4 IUs of oxytocin for a total oxytocin dosage of 24 IUs.
Study NCT03593473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Six intranasal sprays of placebo manufactured to mimic oxytocin nasal spray containing all equivalent ingredients except oxytocin.
Study NCT01710410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active transcranial Direct Current Stimulation
Description: Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
Study NCT02395991 — intervention group
Intervention type: DRUG
Intervention: gadoxetic acid
Description: standard dose of gadoxetic acid (0.025mmol/kg) intravenous administration
Study NCT02395991 — intervention group
Intervention type: OTHER
Intervention: Magnetic resonance imaging (MRI)
Description: Dynamic T1 weighted sequence consist of precontrast, arterial, portal, transitional and hepatobiliary phases.~precontrast, arterial and portal phases (prior to contrast media injection to 60 seconds after contrast media injection) are obtained continuously in free-breathing state. Transitional and hepatobiliary phases are obtained in breath-hold state.
Study NCT01710410 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial Direct Current Stimulation
Description: Brief (30-sec) application of weak electric current (e.g., 2mA) to the scalp.
Study NCT02735889 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Carbonation
Description: 500 ml of beverage consisting of water + 10% glucose and no carbonation
Study NCT02735889 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low carbonation
Description: 500 ml of beverage consisting of water + 10% glucose and low carbonation
Study NCT02735889 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High carbonation
Description: 500 ml of beverage consisting of water + 10% glucose and high carbonation
Study NCT00918996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omission of Bladder Flap Creation
Description: Omission of bladder flap creation by making uterine incision 1 cm above the vesico-uterine reflection without incision and dissection of the bladder peritoneum.
Study NCT04200040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OrienX010 injection
Description: OrienX010 to be used in this study have been developed and manufactured by OrienGene Biotechnology Ltd.~Dacarbazine to be used in this study was manufactured by Sinopharm A-Think Pharmaceutical Co., Ltd.
Study NCT04200040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine (DTIC)
Description: Dacarbazine to be used in this study was manufactured by Sinopharm A-Think Pharmaceutical Co., Ltd.
Study NCT01718977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Weight Supported Treadmill Training
Description: BWSTT protocol will consist of training of individuals with complete SCI on a treadmill with a body weight support system. BWSTT is assisted by three individuals who participate in training. One trainer provides support at the hip, and one trainer at each leg. The participant will be fitted with a harness while seated in their wheelchair and then wheeled up a ramp to the treadmill. Cables attached to the harness will be used to hoist the participant into a standing position. Appropriate body weight support will be set according to the suggested Hocoma locomotor training protocol, in which weight is added until the participant is in dynamic support as indicated by the dynamic gauge on the treadmill. Dynamic support is usually indicated at the weight where participants do not have knee-buckling during a static standing position; however, this may not be observed in all severe, motor-complete SCI participants.
Study NCT01523483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Two micronized progesterone capsules (Utrogestan® 200 mg, i.e. 400 mg of micronized progesterone in sunflower oil) placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
Study NCT01523483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo vaginal capsules
Description: Two placebo capsules placed (soy lecithin and sunflower oil) into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
Study NCT04698525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate Sodium
Description: Comparison between two actives
Study NCT04698525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Memantine
Study NCT01364194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: Periarticular injection with 20 ml of 0.9% normal saline before wound closure.
Study NCT00386841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 10 mg p.o. per day
Study NCT00386841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02086331 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Contrast enhanced ultrasound
Description: Infusion of microbubbles to enhance blood vessels in the leg for ultrasound
Study NCT02086331 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill test
Description: Exposes you to exercise in a controlled environment. We will see if we can detect this change with our new ultrasound protocol
Study NCT02086331 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Contrast enhanced ultrasound
Study NCT03160014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: Drug: SHR3824 20mg/day, oral tablet, single dose
Study NCT02848937 — intervention group
Intervention type: DEVICE
Intervention: Bath with citrate
Description: bath with citrate which allows the equivalence of mass balance (Ca_eq) compared to the concentrate with 3 mM acetate and 1.5 mM of calcium
Study NCT02848937 — intervention group
Intervention type: DEVICE
Intervention: Bath with citrate and Ca_eq
Description: bath with citrate and Ca_eq of concentrate with 3 mM acetate and 1.5 mM of calcium
Study NCT02690909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Redy™ Renal Denervation System
Description: Renal Denervation System
Study NCT03855579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Intraoperative infusion of Levosimendan
Study NCT03855579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Description: Intraoperative infusion of Milrinone
Study NCT02982408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High carbohydrate overfeeding
Description: All participant's individual energy requirement will be determined in mega joules (MJ) per day. The energy requirement will be multiplied by a factor 1.5 for a low physical activity level (PAL). The MJ will be rounded up or down to the nearest whole number.~The participant will receive food corresponding to \~25% additional energy above their calculated energy requirement. The 25% extra energy will be supplied to the participants for 4 weeks in the form of food containing simple carbohydrates. The subjects will be given a daily snack package containing processed foods or refined foods such as sweets, cookies, soft drinks, juice etc. To ensure an adequate energy surplus (i.e. weight gain), physical activity has to be decreased to a low level during the 4 weeks overfeeding period.
Study NCT03329378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 IV, day 1
Study NCT03329378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 6 IV, day 1
Study NCT03329378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab 8mg/kg IV initial dose, followed by 6mg/kg IV , day 1
Study NCT03329378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Pertuzumab 840 mg IV initial dose followed by 420 mg IV, day 1
Study NCT03329378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: Pegfilgrastim 6mg SC, day 2 Cycled as per arm
Study NCT03329378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab 6mg/kg every 21 days to complete 1 year